Want to see IN:PGHL full AI Analyst Report?
PGHL Stock Chart & Stats
₹5751.70
-₹54.70(-1.07%)
At close: 4:00 PM EST
₹5751.70
-₹54.70(-1.07%)
Day’s Range― - ―
52-Week Range₹4,699.70 - ₹6,955.00
Previous CloseN/A
Volume2.65K
Average Volume (3M)456.00
Market Cap
₹90.03B
Enterprise Value₹77.89K
Total Cash (Recent Filing)₹1.85B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)25.1
Beta0.51
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.9%
Share Statistics
EPS (TTM)214.99
Shares Outstanding16,599,382
10 Day Avg. Volume278
30 Day Avg. Volume456
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)15.19
Price to Sales (P/S)5.66
P/FCF Ratio24.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)225
Revenue Forecast (FY)₹15.60B
Bulls Say, Bears Say
Bulls Say
Profitability And Brand StrengthConsistently high gross and net margins, together with rising earnings and renewed revenue growth, indicate durable brand strength and pricing power. This supports profitability through normal cost and demand cycles, although growth has not been perfectly smooth.
Conservative Balance SheetMinimal leverage reduces financial risk and interest burden, giving PGHL flexibility to fund brand investment, working capital, and product development internally. Strong equity backing also improves resilience if consumer demand or input costs become less favorable.
Improving Free Cash FlowThe latest free-cash-flow rebound demonstrates improved cash generation from the operating model and strengthens the company’s ability to support dividends, marketing, and reinvestment. This is particularly valuable for a branded healthcare business reliant on sustained consumer promotion.
Bears Say
Uneven Revenue GrowthThe history of a revenue decline and variable margins shows that growth is not fully consistent, despite recent improvement. Uneven expansion may limit operating leverage and make long-term planning more dependent on successful brand support and category demand.
Volatile Cash ConversionHistorical gaps between earnings and operating cash flow indicate that reported profits have not always converted smoothly into cash. This can constrain internally funded investment and dividends if working capital or other cash requirements become elevated again.
Reduced Asset And Equity BaseA smaller asset and equity base may indicate reduced balance-sheet capacity to absorb setbacks or support materially larger operations over time. While low debt limits risk, the contraction remains a structural watch item alongside the company’s otherwise conservative capital structure.
Procter & Gamble Health Ltd. News
PGHL FAQ
What was Procter & Gamble Health Ltd.’s price range in the past 12 months?
Procter & Gamble Health Ltd. lowest stock price was ₹4699.70 and its highest was ₹6955.00 in the past 12 months.
What is Procter & Gamble Health Ltd.’s market cap?
Procter & Gamble Health Ltd.’s market cap is ₹90.03B.
When is Procter & Gamble Health Ltd.’s upcoming earnings report date?
Procter & Gamble Health Ltd.’s upcoming earnings report date is May 06, 2027 which is in 222 days.
How were Procter & Gamble Health Ltd.’s earnings last quarter?
Procter & Gamble Health Ltd. released its earnings results on May 26, 2026. The company reported ₹57 earnings per share for the quarter.
Is Procter & Gamble Health Ltd. overvalued?
According to Wall Street analysts Procter & Gamble Health Ltd.’s price is currently Overvalued.
Does Procter & Gamble Health Ltd. pay dividends?
Procter & Gamble Health Ltd. pays a Annually dividend of ₹45 which represents an annual dividend yield of 3.9%. See more information on Procter & Gamble Health Ltd. dividends here
What is Procter & Gamble Health Ltd.’s EPS estimate?
Procter & Gamble Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Procter & Gamble Health Ltd. have?
Procter & Gamble Health Ltd. has 16,599,382 shares outstanding.
What happened to Procter & Gamble Health Ltd.’s price movement after its last earnings report?
Procter & Gamble Health Ltd. reported an EPS of ₹57 in its last earnings report. Following the earnings report the stock price went down -5.74%.
Which hedge fund is a major shareholder of Procter & Gamble Health Ltd.?
Currently, no hedge funds are holding shares in IN:PGHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Procter & Gamble Health Ltd.
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.
Technical Analysis
Amrutanjan Health Care Limited
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Zydus Lifesciences Limited
―